UPJOHN's ROGAINE Rx-TO-OTC SWITCH APPLICATION WILL BE REVIEWED
This article was originally published in The Tan Sheet
Executive Summary
UPJOHN's ROGAINE Rx-TO-OTC SWITCH APPLICATION WILL BE REVIEWED by FDA's Nonprescription Drugs Advisory Committee at a July 27 meeting, FDA announced in a June 24 Federal Register notice. Upjohn submitted an NDA for the Rx-to-OTC switch of Rogaine (minoxidil 2% topical solution) as a hair growth stimulant for male pattern baldness (androgenetic alopecia). The meeting will begin at 2 p.m. on July 27 in Conference Rooms D & E of FDA's Parklawn Building, 5600 Fishers Lane, Rockville, Md.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning